Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $10.3MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Formela Jean Francois | Director | Aug 19 '26 | Sale | $14.00 | 28,468 | $398,552 | 141,053 | Aug 21 04:20 PM |
| Atlas Venture Fund Xi, L.p. | Shareholder | Aug 19 '26 | Proposed Sale | $13.22 | 23,584 | $311,780 | — | Aug 19 05:36 PM |
| Atlas Venture Opportunity Fund | Shareholder | Aug 19 '26 | Proposed Sale | $13.22 | 4,884 | $64,566 | — | Aug 19 05:36 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.